Influence of iodization programmes on the epidemiology of nodular goitre by Fiore, Emilio et al.
Accepted Manuscript
Influence of iodization programmes on the epidemiology of nodular goitre
Emilio Fiore , Massimo Tonacchera , Paolo Vitti
PII: S1521-690X(14)00054-2
DOI: 10.1016/j.beem.2014.04.002
Reference: YBEEM 969
To appear in: Best Practice & Research Clinical Endocrinology & Metabolism
Please cite this article as: Fiore E, Tonacchera M, Vitti P, Influence of iodization programmes on the
epidemiology of nodular goitre, Best Practice & Research Clinical Endocrinology & Metabolism (2014),
doi: 10.1016/j.beem.2014.04.002.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 1
Note to author: Pedersen has been cited as reference 85 but is reference 86 
 
Influence of iodization programmes on the epidemiology of nodular goitre 
Emilio Fiore, Massimo Tonacchera and Paolo Vitti 
Department of Clinical and Experimental Medicine, Section of Endocrinology, University of Pisa, Pisa, Italy. 
 
 
E-mail address of authors 
Emilio Fiore: e.fiore@ao-pisa.toscana.it 
Massimo Tonacchera: mtonacchera@hotmail.com 
Paolo Vitti: paolo.vitti@med.unipi.it 
 
Telephone number. +39 (0)50 995001 
Fax : +39 (0) 50 578772 
 
Corresponding author: Paolo Vitti, Endocrinology Unit, University Hospital, University of Pisa, Via Paradisa 2, 
56124, Pisa, Italy 
 
Word count 7428 (including abstract and bibliography)
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 2
Abstract  
Iodine is essential for the synthesis of thyroid hormones. Iodine deficiency can affect human health in different 
ways, and is commonly referred to as iodine deficiency disorders (IDD). These range from defective 
development of the central nervous system during the fetal–neonatal life, to goitre in the adult. Only a few 
countries were completely iodine sufficient before 1990. Since then, a major effort has been made to introduce 
salt iodization to ensure sufficient intake of iodine in deficient areas. Iodine prophylaxis has been shown to exert 
a pivotal role in abating goitre and other iodine-deficiency disorders, and has also been shown to modulate the 
pattern of thyroid diseases. An increased frequency of thyroid autoimmunity and of hypothyroidism has been 
observed after introducing iodization programmes. Nevertheless, available evidence clearly confirms that the 
benefits of correcting iodine deficiency, consisting mainly of reducing nodular goitre and non-autoimmune 
hyperthyroidism, far outweigh the risks of iodine supplementation. 
 
 
Key words: iodine deficiency, iodine prophylaxis, goiter. 
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Introduction 
Iodine is essential for the synthesis of thyroid hormones. Iodine deficiency has multiple adverse effects. Iodine 
intake is insufficient in more than 2 billion people, and therefore deficiency of iodine intake is high on the public 
health agenda worldwide. The term iodine deficiency disorders (IDD) refers to the effect of iodine deficiency in 
individuals. The clinical consequences of iodine deficiency include goitre, which is the most common clinical 
manifestation, and cerebral impairment, ranging from mild cognitive defects to cretinism. The frequency and 
severity of the clinical manifestations are proportional to the magnitude of iodine deficiency (1-5). When severe 
iodine deficiency occurs during pregnancy, it is associated with cretinism and increased neonatal and infant 
mortality. Iodine deficiency remains a major global threat to health and development, and  is the most common 
cause of preventable mental impairment worldwide (6-9). 
 
Iodine metabolism 
Alimentary iodine is absorbed by the gut and is actively concentrated by the thyroid gland. The body of an adult 
contains about 20 mg of iodine, and the thyroid concentrates 70–80% of the total iodine content through the 
sodium–iodine symporter (NIS) located on the basolateral surface of thyrocytes. A normal adult uses about 80 
mg/day of iodide to produce thyroid hormones. Ninety per cent of the plasma iodine is excreted by the kidney, 
and only a small amount in the faeces. 
Iodine requirement changes with age and in relation to various physiological conditions (7). According 
to the World Health Organization/International Council for the Control of Iodine Deficiency Disorders 
(WHO/ICCIDD), the recommended nutrient intake of iodine is 90 mcg/day in infants and children under 6 years 
of age, 120 mcg/ day in children 6–12 years of age, and 150 mcg/day in adults. During pregnancy, the 
recommended intake increases to 250 mcg/day. The recommended intake in lactating women is 250 mcg/ day to 
compensate for the iodine loss in breast milk. 
When iodine intake is slightly insufficient (i.e. < 100 mcg/day), thyroid stimulating hormone (TSH) 
induces a higher NIS expression, with an increase of thyroid iodine uptake and preferential synthesis of T3, thus 
allowing a normal content of intrathyroidal iodine. In chronic iodine deficiency, the thyroid content of iodine 
progressively decreases, the metabolic balance of iodine becomes negative, and goitre ensues (8;10;11). 
 
Patogenesis of goitre and iodine nutrition 
Nodular goitre is probably a lifelong condition that starts in adolescence or at puberty. Minimal diffuse 
enlargement of the thyroid gland is found in many teenage boys and girls, and is almost a physiologic response 
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to the complex structural and hormonal changes occurring at this time. It usually regresses but, occasionally, 
(much more commonly in girls) it persists and undergoes further growth during pregnancy (12;13). 
Marine (14) first developed the concept, that the thyroid first goes through a period of hyperplasia in 
response to iodide deficiency as a consequence of the resulting TSH stimulation (15). Eventually, the thyroid 
enters a resting phase characterized by colloid storage. This is possibly as a result of iodide repletion or a 
decreased requirement for thyroid hormone. The recurrence of these two phases would eventually result in the 
formation of multinodular goitre (16;17), at least in genetically predisposed individuals (18;19). Over time, 
functional autonomy may occur (20), with suppression of TSH. Experimental data obtained in rats fed with an 
iodine-deficient diet, have clarified the natural evolution of the goitre.  
Thyroid follicules are functionally heterogeneous, and cell clones differ for their replicative capacity 
and ability to produce thyroid hormones. The clonal development of follicles with high replication capacity will 
induce the onset of non-functioning (cold) or hyperfunctioning (hot) nodules, in which the uptake and thyroid 
hormone synthesis is independent from TSH stimulation. The increase of size and function of hot nodules 
induces initially a slight enhancement of thyroid hormone production, which is characterized by serum thyroid 
hormones within normal limits and a suppressed TSH (subclinical hyperthyroidism). With the further increase of 
thyroid hormone production, hyperthyroidism evolves from subclinical to clinical, in which an increased level of 
thyroid hormones is associated with a low TSH (21). The molecular mechanisms involved in the development of 
thyroid functional autonomy have recently been partially identified. TSH receptor or Gsά-protein undergo 
somatic point mutation that induce a permanent and TSH-independent activation of the adenylate–
cyclasepathway (22;23). 
 
Natural history and epidemiology of goitre and iodine nutrition 
In many countries, iodine deficiency largely contributes to the high prevalence of diffuse and nodular 
goitre (24). People with multinodular goitre usually seek medical attention because they occasionally discover a 
lump in the neck. Sometimes, the increase in the size of the goitre will cause pressure symptoms, such as 
difficulty in swallowing, cough, respiratory distress, or the feeling of a lump in the throat. Commonly, the goitre 
is discovered by a physician in the course of an examination for some other condition. Sometimes, the patient 
seeks medical attention because of cardiac irregularities or congestive heart failure, which proves to be the result 
of slowly developing thyrotoxicosis. 
In studies conducted in areas with adequate iodine intake, a lower prevalence of goitre is usually 
reported. In the Whickham survey (25), 15.5% of participants had goitres, with a female–male ratio of 4.5:1. In 
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the Framingham study (26), 1% of participants between 30 and 59 years had multinodular goitres (at thyroid 
palpation). In an iodine-deficient area, the goitre prevalence was 35% among people aged between 12 and 14 
years, and about 70% in people aged between 35 and 75 years (27). The prevalence of thyroid nodules was much 
higher when evaluated by ultrasound: up to 50% of the general population have thyroid nodules, even when the 
thyroid is normal at palpation (28). Consequently, autopsy studies have shown the presence of single or multiple 
nodules in one-half of the population (29).  
A few epidemiological studies have evaluated the clinical evolution of goitre. In the Whickham survey 
(25), 20% of women and 5% of men who had goitres in the initial survey showed no evidence of goitre in a 
follow-up survey (30). An average growth rate in the multinodular goitre of 5–20% was reported in iodine-
sufficient areas (31). On the basis of the results of the Framingham survey, the estimated lifetime risk for 
developing a nodule is 5–10% (26). Thyroid nodule size can increase, decrease, or remain stable, and thyroid 
nodules may eventually also disappear over time. Solid nodules more frequently increase, whereas cystic 
nodules can shrink or disappear. If the goitre has been present for some time, autonomous function of the 
nodules and eventually hyperthyroidism develop. The rate of progression from euthyroidism to subclinical and 
overt hyperthyroidism is about 10%. In a Dutch study of 90 people with euthyroid multinodular goitre, mainly 
women with a mean age of 55 years, eight became hyperthyroid within 7 years, and all of them had autonomous 
function before becoming hyperthyroid (32). In a study conducted at the Mayo Clinic, 60% of people with multi-
nodular goitre over 60 years had thyrotoxicosis (33). The average duration of the goitre before the onset of 
thyrotoxicosis was 17 years; the longer the goitre had been present, the greater the tendency for thyrotoxicosis to 
develop. Iodine intake has been shown to modulate the pattern of thyroid diseases in cross-sectional studies 
comparing populations living in areas characterized by different iodine intake (24). In iodine-deficient countries, 
non-autoimmune hyperthyroidism is more frequent, being the natural evolution of goitre, the development of 
thyroid autonomy, and eventually of thyrotoxicosis. On the other hand, studies in populations living in areas 
with varying iodine intakes, in the UK (30),  Denmark, and  Iceland (34), have shown that the frequency of 
thyroid autoimmunity and of hypothyroidism is higher in iodine replete than in iodine deficient populations.  
In Denmark, the Danish investigation on iodine intake and thyroid disease (DanThyr)  programme has 
been developed, with the aim of monitoring iodine intake and thyroid diseases that could secure optimal iodine 
nutrition of the Danish population (35).The first cohort study of DanThyr programme was started before iodine 
fortification, and took place in and around the city of Aalborg in Jutland, and in Copenhagen (36). The two 
geographical regions cover the main difference in levels of iodine intake in Denmark caused by different levels 
of iodine in ground water (36;37), and goitre was more frequent in areas with lower iodine intake. In a survey 
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conducted in Pescopagano (27), a southern Italian village with mild-to-moderate iodine deficiency, an age-
dependent increased prevalence of goitre, thyroid nodularity, and functional autonomy was observed. Overt 
hyperthyroidism was twice as high as that reported in iodine-sufficient areas, mainly due to an increased 
frequency of toxic nodular goitre. 
 
Iodine prophylaxis  
Since iodine was removed from the soil during the era of wide glaciations, the amount of iodine in potable water,  
vegetable and animal food in many areas of the world is poor. The endemic goitre is more common in 
mountainous regions, but is also present in plane and coastal regions. It is more commonly seen in extra-urban 
populations, especially rural populations, who eat local foods that are low in iodine. In fact, economic status 
rather than geographical location is the main determinant of the quality of the food and of the iodine content. In 
many countries salt, bread, and milk are fortified with iodine in efforts to eradicate iodine deficiency. Other 
sources of iodine are compounds used by industry and agriculture, supplements, disinfectants, and medicines. 
The most effective method to improve iodine nutrition is through salt iodization (7). Iodization of all salt for 
human and livestock consumption (universal salt iodination or USI) is not, however, commonly achieved. Iodine 
is added to kitchen salt at a level of 20–40 mcg/kg of salt in the form of potassium iodide (KI) or potassium 
iodate (KIO3). The fortification with iodine of baker’s salt, drinking water, and irrigation water has been used, 
but this method is less practical. When iodization of water is not feasible, iodine can be added to oil. Iodized oil 
can be given orally or by intramuscular injection (200–400 mg of iodine per year). Iodine can be also given as KI 
(30 mg monthly) or KIO3. In areas where a salt-iodization programme covering at least 90% of households has 
been sustained for at least 2 years, and the median urinary iodine indicates iodine sufficiency, there is no need to 
supplement pregnant and lactating women. In other areas, women should be provided with an intake of at least 
150 mcg/day of iodine for a long period before conception to restore intra-thyroidal stores and to ensure a better 
maternal thyroid. 
 
Worldwide status of iodine deficiency 
 Only a few countries (Switzerland, some of the Scandinavian countries, Australia, USA, and Canada) 
were completely iodine sufficient before 1990. Since then, a major effort has been made has to introduce salt 
iodization as a safe, cost-effective, and sustainable strategy to ensure sufficient intake of iodine in deficient areas 
(38-50). Iodized salt programmes are now implemented in many countries worldwide, and two-thirds of the 
world’s population (71%) is estimated to be covered by iodized salt (1). 
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The worldwide state of iodine nutrition was reviewed in 2008. The data were based on urinary iodine 
surveys carried out between 1997 and 2006 in 41 countries, and estimates obtained in 2003 in 89 countries (7). 
The data covered 92.4% of the world population aged between 6 and 12 years, and showed that 31.5% (264 
million) of school-age children had insufficient iodine intakes (below 100 mg/L). The lowest prevalence of 
iodine deficiency was in the Americas (10.6%), where over 90% of households consumed iodine-enriched salt. 
The worldwide state of iodine nutrition was again assessed in 2011 (51). In this survey, data on urinary iodine 
cover 96.1% of the world’s population of school-age children. Since 2007, new national data were available for 
58 countries.  Between 2003 and 2011, the number of iodine-deficient countries decreased from 54 to 32, and the 
number of  countries with adequate iodine intake increased from 67 to 105. A steady progress was observed in 
Europe, the Eastern Mediterranean, the South-East of Asia and the Western Pacific regions, largely due to 
strengthened salt iodization programmes and improved monitoring (52); however, only a negligible progress was 
observed in Africa. Paradoxically, rich European countries lacking specific iodine prophylaxis programmes 
remain mildly iodine deficient (51). The prevalence of iodine deficiency in Europe has reduced by 30% between 
2003 and 2010, but 44% of school-age children still have insufficient iodine intake. Although the UK was 
considered iodine sufficient for some time, median urinary iodine was 80 mg/L in 14- and 15-year-old school 
(53). In Italy, iodine deficiency was initially shown in the mountainous regions of the Alps, but subsequent 
epidemiological studies demonstrated its presence in all areas, particularly in southern and insular regions. 
Recently, the status of iodine nutrition was assessed in southern Italian regions (54). Urinary iodine was 
randomly measured in 26,913 participants, and was lower than 100 mcg/L in 64.3% and lower than 50 mg/L in 
34.9% of samples. Median urinary iodine in non-urban areas was significantly lower than in urban areas (69 v 79 
mg/L; P < 0.0001).  
 
Iodine prophylaxis and epidemiology of goitre 
Iodine supplementation affects the epidemiology and eventually the natural history of goitre. Early Chinese 
medical writings in around 3600 B.C. were the first to record the decreases in goitre size upon ingestion of 
seaweed and overcooked sea sponge (55). Although iodine was yet to be discovered, these remedies remained 
effective, and their use continued globally, as was documented in writings by Hippocrates, Galen, Roger, and 
Arnold of Villanova in later centuries (55). The discovery of iodine was made incidentally during the early part 
of the 19th century (55). Shortly after, J.F. Coindet, a physician in Switzerland, published his observations that 
administration of iodine (as grains in distilled alcohol) was able to decrease the size of his patients’ goitres (16).           
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In 1852, Adolphe Chatin, a French chemist, was the first to publish the hypothesis of population iodine 
deficiency associated with endemic goitre (56). This was confirmed by Eugen Baumann, who, in 1896, reported 
the discovery of iodine within the thyroid gland (57). In the 1830s, the French nutritional chemist, Jean Baptiste 
Boussingault, observed that the prevalence of goitre was increased in areas where naturally occurring iodized 
salt was infrequently consumed, and recommended the distribution of naturally iodized salt for public 
consumption. Iodine supplementation, however, primarily through the fortification of table salt, did not begin 
until the early 1920s, and occurred initially in Switzerland and the USA. 
Between 1916 and 1920, the first large-scale trials with iodine were carried out in Akron by Marine and 
Kimball (58). In that investigation, about 5000 girls between the ages of 11 and 18 years took part. Marine et al. 
(59) published a series of papers reporting a significantly decreased frequency of goitre in children treated with 
iodine (0.2%), compared with children who did not receive iodine supplementation (> 25%).  
In Switzerland’s an iodized salt programme has been operating uninterrupted since 1922. Before its 
introduction, Switzerland was severely iodine deficient. In 1919, Klinger, noting the success of the US studies, 
recommended prophylaxis with iodine tablets at Swiss schools and iodized salt for the general population. The 
first canton in which iodized salt was introduced was Appenzell AR, in 1922, thanks to the efforts of the surgeon 
Eggenberger (57). He pushed the local government to allow the sale of salt, iodized at 7.5 mg/kg, with 
spectacular results: goitre in newborns disappeared, no new cretins were born, and goitres in children were 
reduced in size or disappeared (57). 
In the USA, iodized salt first became available on grocery shelves in Michigan in 1924, encouraged 
largely by the series of reports by Cowie, Marine, and others in the preceding years (59). Before starting the 
iodine prophylaxis programme, surveys on goitre in schoolchildren and on the iodine content of drinking water 
were conducted for the first time in four representative counties of this State. The prevalence of goitre was 
38.6% among the 65,537 schoolchildren studied. Salt containing potassium iodide (1 part in 5000) was 
introduced, and by 1929 was reduced to 9% (59). Bursh and Altland  in 1952 conducted follow-up surveys of 
53,785 participants in the same counties, and found a goitre prevalence of only 1.4%.  
In a recent survey conducted in Pescopagano (60), an Italian village with a previous moderate iodine 
deficiency, the introduction of an iodine prophylaxis programme on a voluntary basis resulted in a significant 
reduction of the prevalence of goitre (Fig. 1), mainly due to the reduction of diffuse goitres in 2010 compared 
with the previous survey in 1995 (10.3% v 34.0%). The overall prevalence of nodular goitre was not 
significantly different in the two surveys. When age was taken into account, however, its frequency was 
significantly lower in 2010 than in 1995 in people aged between 26 and 35 years (3.8% v 11.3%); however, no 
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difference was observed in people aged over 35 years. The absence of a significant difference in the frequency of 
nodular goitre in people older than 35 years may be because, in  most people this age, the process of 
morphological changes and goitre development started before the increase in iodine intake (60). 
 
Monitoring iodine prophylaxis 
The methods for assessing iodine nutrition in populations are as follows: determination of goitre prevalence, 
urinary iodine concentration, serum TSH level in newborns, and serum thyroglobulin level (Tg) (61). 
Goitre size can be measured by neck inspection and palpation or by thyroid ultrasonography. Thyroid ultrasound 
is more sensitive and specific than palpation, but requires valid reference intervals for thyroid volume (62;63). 
Goitre surveys as indicators of iodine sufficiency are usually carried out  in school-age children because 
participants are easy to recruit, and reflect the actual effect of iodine deficiency in humans. The WHO 
established a total goitre rate in school children to define the severity of iodine deficiency. Rates below 5.0% 
indicate iodine sufficiency; 5.0–19.9%, mild deficiency 20.0–29.9%, moderate deficiency, and above 30.0%, 
severe deficiency (7).  
Because more than 90% of dietary iodine is excreted in the urine, measurement of urinary iodine 
concentration is a reliable index of recent dietary iodine intake (64). Its determination in a population is directly 
correlated with the frequency of goitre and the disorders of iodine deficiency. A UIC level of less than 100 mg/L 
in school-aged children indicates insufficient iodine intake; iodine deficiency is severe at less than 20 mg/L, 
moderate at 20–49 mg/L, and mild at UIC 50–99 mg/L. An adequate UIC value is 100–199 mg/L, and a value 
greater than 200 mg/L can induce thyrotoxicosis and other adverse effects in susceptible groups (65). 
Thyroid-stimulating hormone concentrations obtained during screening to detect congenital 
hypothyroidism in newborns is useful to assess iodine nutrition, because an increase of TSH is a mechanism 
though which the fetus adapts to iodine deficiency. Indeed, iodine deficiency causes a shift toward higher TSH 
values in the neonatal screening of congenital hypothyroidism. A TSH value greater than 5 mU/L in whole blood 
collected 3–4 days after birth and lasting for a few weeks in more than 3% of newborns indicates iodine 
deficiency in a population.  
Thyroglobulin (Tg) is the most abundant intrathyroidal protein. Serum Tg is higher in iodine-deficient 
than in iodine-sufficient areas as a consequence of TSH stimulation. The higher rate of goitre and falls quickly 
with iodine prophylaxis (66). 
In the 1990s, iodized salt programmes were introduced in many countries. It was increasingly reported 
that, in areas previously endemic for goitre, thyroid size decreased as iodine intake increased; however, thyroid 
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size did not return to normal for months or years after correction of iodine deficiency. Prevalence of goitre also 
remained elevated (> 5%), particularly among older children and adults (67). This problem was had already been 
recognized in the early 1800s by Coindet in Geneva, who noted that goitres often did not completely disappear 
even after long-term treatment with oral iodine (61). Because of this long time lag in the resolution of goitre, the 
frequency of goitre is difficult to interpret for several years after iodized salt introduction, because it reflects both 
a population’s history of iodine nutrition as well as its present status.  A study conducted among school children 
in an area of Eastern Tuscany (68) showed that the iodized salt prophylaxis was able to prevent the development 
of goitre in children born after the implementation of iodized salt consumption and  further controlled thyroid 
enlargement in older children; however, it was found to be less effective in reducing goitre size in children 
exposed to iodine deficiency in the first years of life. 
Following recommendations from WHO in 1993 (61), most national monitoring programmes were 
measuring both the prevalence of goitre and the urinary iodine concentration. In contrast, to the slow response of 
the goitre frequency, however, urinary iodine concentration rapidly increased into the normal range after the 
introduction of adequately iodized salt because they reflected recent iodine intake. This resulted in many 
programmes reporting a discrepancy between the degrees of residual iodine deficiency in the population, as 
indicated by the urinary iodine concentration compared with the prevalence of goitre (69). This implies that the 
time lag to normalization of thyroid size after the introduction of iodized salt in an area of chronic iodine 
deficiency could be a decade or more. To emphasize the limitation of the measurement of the frequency of goitre 
in judging the short-term efficacy of salt iodization program, in 2000, WHO recommended that the median 
urinary iodine concentration be used as the primary indicator of the effect of iodized salt. Assessment of goitre 
by palpation and hopefully by ultrasonography, however, is still a useful tool in areas in which iodized salt has 
not yet been introduced or  when there are concerns that iodine deficiency may be re-emerging (53;70). 
 
Iodine prophylaxis and the spectrum of thyroid diseases 
After the introduction of iodine prophylaxis, increased incidences of hyperthyroidism were observed as a result 
of the development of iodine-induced thyrotoxicosis in people with pre-existing autonomous multinodular goitre 
(71). In the USA, after the beginning of iodine supplementation in 1924, Hartsock in 1926 described an outbreak 
of thyrotoxicosis in adults who took iodized salt living in the Great Lakes region (72). This condition is transient 
and correlated to the level of iodine deficiency and the amount of iodine administered. In 1980 in  Switzerland, 
the iodine content in salt was increased from 7.5 to 15 mg/kg, doubling iodine intake;  incidence of toxic nodular 
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goitre increased by 12% in the first 2 years after the increase, but then declined to a level of only 25% of the 
initial incidence (73;74).  
In Denmark, starting from June 1998, a programme of voluntary use of iodized salt was launched by the 
Danish Food and Veterinary Administration in cooperation with salt manufactures and the food industry. After 2 
years, it turned out that the programme had failed and, therefore, a mandatory programme was introduced during 
the period July 2000–April 2001(75). The DanTyr program has documented the pattern of thyroid disease after 
careful introduction of iodized salt (76). The overall incidence rate of hyperthyroidism increased (baseline, 
102.8/100,000/ year; after salt iodization 138.7/100,000/year). Hyperthyroidism increased in both sexes and in 
all age groups, many of the new cases were observed in young people, and were presumably autoimmune in 
origin. The investigators suggested that further monitoring is expected to show a decrease in the number of 
elderly people suffering from nodular hyperthyroidism.These data emphasize the importance of regular 
monitoring of iodine status to detect low and excessive intakes of iodine. In the survey conducted in 
Pescopagano (60), after the introduction of a iodine prophylaxis programme on a voluntary basis, thyroid 
autonomy was not observed in younger people (Fig. 2), and was associated with a significant reduction of the 
frequency of hyperthyroidism caused by toxic nodular goitre in older age. The investigators did not observe an 
increased frequency of hyperthyroidism after the beginning of iodine prophylaxis as reported in other studies 
(77;78), conceivably because of the lower level of iodine supplementation in this population. Taken together, 
these data indicate that iodine prophylaxis is associated with a reduced frequency of thyroid autonomy in 
younger people, and of toxic nodular goitre in older people. This phenomenon may have a relevant effect on the 
health of this population, as thyrotoxicosis is associated with increased morbidity, cardiovascular morbidity in 
particular, which leads to increased mortality, especially in elderly people (79-81).  
A potential side-effect of iodine supplementation is the worsening or the induction of autoimmune 
thyroiditis (82;83). Cross-sectional studies of populations with different iodine intakes in the UK (30), in 
Denmark, and in Iceland (34) have shown that the frequency of thyroid autoantibodies and hypothyroidism is 
higher in iodine replete than in iodine deficient populations. Boukis et al. (84) showed that, in people with goitre 
from a mildly iodine-deficient area in Greece treated with iodized oil, thyroid autoantibodies, undetectable 
before treatment, became positive in 42.8% of the people 3 and 6 months later. Recently, Pedersen (85) found an 
increased prevalence of thyroid autoantibodies after the beginning of a cautious iodization programme, 
supporting the view that even a small increase of iodine supplementation may be associated with an increased 
thyroid autoimmunity. An increased frequency of hypothyroidism has also been reported after the careful 
introduction of iodized salt in Denmark (24;85).The DanTyr program (86) has documented  a modest increase 
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of the incidence rate of hypothyroidism in the 7 years after the introduction of the national program of 
salt iodization (baseline, 38.3/100,000/year; after salt iodization, 47.2/100,000/ year, v baseline, relative 
risk, 1.23; 95% CI, 1.07 to 1.42). A geographic difference was observed because hypothyroidism increased 
only in the area with previous moderate iodine deficiency. The increase occurred in young and middle-
aged adults (87). Similar findings were reported in the Pescopagano survey, in which an increased frequency of 
thyroid autoantibodies, and of Hashimoto’s thyroiditis were observed after the beginning of iodine prophylaxis 
(88). That study showed that iodine intake modulates the pattern of thyroid diseases, even with slight 
differences, and below the dose of 150 mcg daily recommended for preventing IDD. Therefore, any level of  
change in iodine intake modifies the expression of thyroid diseases. Thyroglobulin (Tg) is an important 
target in iodine-induced autoimmune response, iodine being an essential component of Tg. As far as the 
induction of thyroid autoimmunity is concerned, the effect of iodine supplementation is correlated with 
the intrinsic characteristics of Tg, namely its modifications induced by post-translational iodination. 
 
Summary 
Iodine is essential for the synthesis of thyroid hormones, and iodine deficiency has several consequences for 
human health, referred to as iodine deficiency disorders. These range from defective development of the central 
nervous system during the fetal-neonatal life, to goitre in the adult. Iodine prophylaxis through iodized salt has 
been shown to exert a pivotal role in abating iodine deficiency disorders. Iodine intake strongly affects the 
pattern of thyroid diseases reducing the prevalence of goitre, thyroid autonomy and non-autoimmune 
hyperthyroidism, but increasing  the frequency of thyroid autoimmunity and mild hypothyroidism. It is important 
to underline, however, that iodine-induced adverse effects can be almost entirely avoided by adequate and 
sustained quality control and monitoring of iodine supplementation. Available evidence clearly confirms that the 
benefits of correcting iodine deficiency far outweigh the risks of iodine supplementation (89;90). 
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Practice Points 
• Iodine is essential for the synthesis of thyroid hormones 
• Iodine deficiency has multiple adverse effects, including goitre, which is the most common clinical 
manifestation, and cerebral impairment, ranging from mild cognitive defects to cretinism. 
• Iodine prophylaxis, through iodized salt, has been shown to exert a pivotal role in abating the frequency 
of iodine deficiency disorders. 
• Iodine intake strongly affects the pattern of thyroid diseases by reducing the prevalence of goitre, 
thyroid autonomy, and non-autoimmune hyperthyroidism, but also increases the frequency of thyroid 
autoimmunity and mild hypothyroidism. 
• Available evidence favours the interpretation that the benefits of correcting iodine deficiency far 
outweigh the risks of iodine supplementation. 
 
 
Research agenda 
• Both low and excessive intakes of iodine affect the frequency of thyroid disorders. Large prospective 
epidemiological studies would better define the optimal iodine intake. These data emphasize  the 
importance of regular monitoring of iodine status after the introduction of iodine prophylaxis. 
• Thyroglobulin (Tg) is an important target in the iodine-induced autoimmune response, iodine being an 
essential component of Tg. The effect of iodine is correlated with the intrinsiccharacteristics of Tg, 
namely its modifications induced by post-translational iodination. The understanding of these changes 
may shed light on iodine-induced thyroid autoimmunity. 
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Legend of figures 
Figure 1. Frequency of goiter in subjects resident in Pescopagano in 1995 (white columns) and in 2010 (grey 
columns). The prevalence of goiter progressively increased with age both in 1995 and 2010 and in each class of 
age was significantly lower in 2010 compared to 1995, with the exception of subjects older than 75 years. * = p 
< 0.001  
 
Figure 2. Frequency of functional thyroid autonomy  in subjects resident in Pescopagano in 1995 (white 
columns) and in 2010 (grey columns). The frequency of functional thyroid autonomy was not significantly 
different between 2010 and 1995 in each class of age due to the small number of subjects, but was significantly 
lower in 2010 than in 1995 in subjects younger than 45 years grouped together (Fischer test p = 0.004), while no 
significant difference was observed in subjects older than 45 years (not shown in figure). 
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